Epidemiology and Costs of Hypertension-related Disorders

Title: Epidemiology and Costs of Hypertension-related Disorders

Volume: 17 Issue: 28

Author(s): Aldo Leone, Linda Landini and Aurelio Leone

Affiliation:

Keywords: Epidemiological transition, hypertension, cardiovascular disorders, trial(s), cost-benefit ratio, smoking, lipoproteins, vulnerable plaque, thrombin, diabetes

Abstract: Epidemiological surveys demonstrate undoubtedly that cardiovascular disorders caused or associated with hypertension are at a high risk of non-fatal or fatal events and occurring with a great rate. Ischaemic heart disease with effort angina and myocardial infarction, often unrecognized myocardial infarction, stroke and transient ischaemic attack may be observed more frequently than other cardiovascular disorders in hypertensive patients.

Large-scale trials do not support the hypothesis that effective benefits are reached by current non-pharmacological or pharmacological prevention which need enormous costs to public health.

Lowering blood pressure is the main target to reach in an attempt to reduce cardiovascular complications in hypertensive patients. Therefore, the costs-benefit ratio, which estimates public health costs, needs yet marked improvement since the public health expenses are heaviest with results that do not support the economic effort.

Statistically, quantitative measures to modify the current regimen need to better evaluate both public health costs and reached benefits.

Cite this article as:

Leone Aldo, Landini Linda and Leone Aurelio, Epidemiology and Costs of Hypertension-related Disorders, Current Pharmaceutical Design 2011; 17 (28) . https://dx.doi.org/10.2174/138161211798157739